Efficacy and safety of sildenafil in Asian males with erectile dysfunction and cardiovascular risk.
Artículo
en Inglés
| IMSEAR
| ID: sea-44614
ABSTRACT
OBJECTIVE:
Assess the effectiveness of sildenafil in Asian males with erectile dysfunction (ED) and one or more of the co-morbidities, mild-to-moderate hypertension, dyslipidemia, and diabetes. MATERIAL ANDMETHOD:
A six-week, double-blind, randomized, placebo-controlled, multicenter study was carried out in Thailand, Malaysia and Singapore. One hundred and fifty five male subjects were randomized (21) to sildenafil (n = 104) or placebo (n = 51). Sildenafil was started at 50 mg and increased (100 mg) or decreased (25 mg) at week 2 if necessary.RESULTS:
On the primary efficacy endpoint, sildenafil-treated subjects had significantly better scores on the International Index of Erectile Function (IIEF) questions 3 and 4 than placebo (p < 0.001, both questions). When accumulated into IIEF domains, all five domains were significant in favor of sildenafil. In addition, sildenafil-treated subjects were more satisfied with treatment and had a higher intercourse success rate. The majority of adverse events were mild in severity; the most commonly reported treatment-related events were dizziness (7.7%) and tinnitus (2.9%).CONCLUSION:
Sildenafil (25, 50, and 100 mg) was found to be an effective, safe, and well-tolerated treatment for ED in the present study population of Thai, Malaysian, and Singaporean males who also had increased cardiovascular risk
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Inhibidores de Fosfodiesterasa
/
Piperazinas
/
Purinas
/
Singapur
/
Sulfonas
/
Tailandia
/
Humanos
/
Masculino
/
Enfermedades Cardiovasculares
/
Factores de Riesgo
Tipo de estudio:
Ensayo Clínico Controlado
/
Estudio de etiología
/
Factores de riesgo
País/Región como asunto:
Asia
Idioma:
Inglés
Año:
2007
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS